Aortic stenosis medical therapy

Revision as of 21:04, 4 March 2014 by Alejandro Lemor (talk | contribs) (/* AHA/ACC 2014 Guideline for the Management of Patients With Valvular Heart Diseases {{Cite web | last = | first = | title = 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary | url = http://circ.ah...)
Jump to navigation Jump to search

Aortic Stenosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Aortic Stenosis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Cardiac Stress Test

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography

Cardiac Catheterization

Aortic Valve Area

Aortic Valve Area Calculation

Treatment

General Approach

Medical Therapy

Surgery

Percutaneous Aortic Balloon Valvotomy (PABV) or Aortic Valvuloplasty

Transcatheter Aortic Valve Replacement (TAVR)

TAVR vs SAVR
Critical Pathway
Patient Selection
Imaging
Evaluation
Valve Types
TAVR Procedure
Post TAVR management
AHA/ACC Guideline Recommendations

Follow Up

Prevention

Precautions and Prophylaxis

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Aortic stenosis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Aortic stenosis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Aortic stenosis medical therapy

CDC on Aortic stenosis medical therapy

Aortic stenosis medical therapy in the news

Blogs on Aortic stenosis medical therapy

Directions to Hospitals Treating Aortic stenosis medical therapy

Risk calculators and risk factors for Aortic stenosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Mohammed A. Sbeih, M.D. [2]; Cafer Zorkun, M.D., Ph.D. [3]; Assistant Editor-In-Chief: Kristin Feeney, B.S. [4]

Overview

While medical therapy may improve the symptoms of patients with aortic stenosis, medical therapy does not prolong life expectancy. Aortic valve replacement remains the definitive treatment of symptomatic aortic stenosis and it improves both the symptoms and life expectancy of patients with aortic stenosis. When pharmacological therapies are used, extreme caution must be taken in the administration of vasodilators as excess vasodilation may lead to hypotension, a reduction in perfusion pressure to the heart, a further decline in cardiac output and further hypotension. This downward spiral can be fatal and must be avoided at all costs.

Pharmacotherpay

Lipid-Lowering

More rapid progression of aortic stenosis has been associated with traditional risk factors for atherosclerosis. Based on the similarities that exist between calcific aortic stenosis and atherosclerosis in terms of their pathological features and risk factors, there has been a substantial interest to modify the progression of calcific aortic stenosis with the administration of cholesterol lowering agents such as statins. A number of small, observational studies have demonstrated an association between low cholesterol levels and decreased progression of aortic stenosis, and even regression of calcific aortic stenosis. Administration of rosuvastatin has been associated with a slowing of aortic stenosis progression in a small study[1].

Vasodilators

Extreme care should be taken to avoid excess vasodilation in the patient with critical aortic stenosis which could precipitate a downward spiral of low forward output, impaired subendocardial perfusion, ischemia and further reduction in forward output.

Nitroglycerin is helpful in relieving angina pectoris symptoms but should be used cautiously to avoid hypotention and excess vasodilation.

Diuretics

Diuretics should be administered cautiously to avoid dehydration, hypovolemia and a significant reduction in cardiac output.

Other Therapies

Beta blockers and angiotensin-converting enzyme inhibitors are generally safe for asymptomatic patients with preserved left ventricular systolic function.

Sodium Restriction

If the patient has symptoms of heart failure, the patient should be placed on sodium restriction.

ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease (DO NOT EDIT)[2]

Class IIa
"1. It is reasonable to treat systemic hypertension in patients with AS while monitoring diastolic blood pressure to avoid reducing coronary perfusion. (Level of Evidence: C)"
"2. It is reasonable to administer beta blockers in patients with BAV and aortic root dilatation. (Level of Evidence: C)"
"3. It is reasonable to use long-term vasodilator therapy in patients with AR and systemic hypertension while carefully monitoring diastolic blood pressure to avoid reducing coronary perfusion. (Level of Evidence: C)"
Class IIb
"1. It may be reasonable to treat patients with BAV and risk factors for atherosclerosis with statins with the aim of ‘‘slowing down degenerative changes in the aortic valve and preventing atherosclerosis. (Level of Evidence: C)"


AHA/ACC 2014 Guideline for the Management of Patients With Valvular Heart Diseases [3]

Class I
"1. Hypertension in patients at risk for developing AS (stage A) and in patients with asymptomatic AS (stages B and C) should be treated according to standard GDMT, started at a low dose, and gradually titrated upward as needed with frequent clinical monitoring. (Level of Evidence:B) "
Class IIb
"1. Vasodilator therapy may be reasonable if used with invasive hemodynamic monitoring in the acute management of patients with severe decompensated AS (stage D) with New York Heart Association (NYHA) class IV heart failure symptoms. (Level of Evidence: C)"
Class III
"1. Statin therapy is not indicated for prevention of hemodynamic progression of AS in patients with mild-to-moderate calcific valve disease (stages B to D) (54-56). (Level of Evidence: A) "

References

  1. Moura LM, Ramos SF, Zamorano JL; et al. (2007). "Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis". J. Am. Coll. Cardiol. 49 (5): 554–61. doi:10.1016/j.jacc.2006.07.072. PMID 17276178.
  2. Warnes CA, Williams RG, Bashore TM, Child JS, Connolly HM, Dearani JA, del Nido P, Fasules JW, Graham TP, Hijazi ZM, Hunt SA, King ME, Landzberg MJ, Miner PD, Radford MJ, Walsh EP, Webb GD, Smith SC, Jacobs AK, Adams CD, Anderson JL, Antman EM, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura RA, Page RL, Riegel B, Tarkington LG, Yancy CW (2008). "ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease). Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons". Journal of the American College of Cardiology. 52 (23): e143–263. doi:10.1016/j.jacc.2008.10.001. PMID 19038677. Retrieved 2013-01-09. Unknown parameter |month= ignored (help)
  3. "2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary". Retrieved 4 March 2014.

Template:WH Template:WS